TABLE 2.
Expression of CIP2A in various tumor tissues and its clinical significance.
| Type of cancer | Positive rate | Relationship with survival rate | Relationship with prognosis | References |
|---|---|---|---|---|
| NPC | 90.7% (254/280) | + a | + | Liu et al. (2014b) |
| Tongue cancer | 97.3% (71/73) | + | + | Böckelman et al. (2011b) |
| Oral cancer | 100% (133/133) | + | + | Velmurugan et al. (2019) |
| Oral squamous cell carcinoma | 54.3% (19/35) | ± | ± | Alzahrani et al. (2020) |
| HNSCC | 78.6% (11/14) | - b | - | Junttila et al. (2007) |
| 80.8% (42/52) | + | + | Routila et al. (2016) | |
| 82.7% (43/52) | + | - | Ventelä et al. (2015) | |
| Thyroid carcinoma | 85.3% (81/95) | + | + | Chao et al. (2016) |
| Lung cancer | 84.7% (61/72) | - | - | Peng et al. (2015) |
| NSCLC | 72.2% (65/90) | + | + | Dong et al. (2011) |
| 76.3% (74/97) | + | + | Xu et al. (2012) | |
| 88.3% (184/209) | + | + | Cha et al. (2017) | |
| Breast cancer | 39.4% (13/33) | + | - | Côme et al. (2009) |
| 35% (448/1280) | + | + | Yu G et al. (2013) | |
| 46% (565/1228) | - | + | Laine et al. (2013) | |
| 100% (46/46) | - | - | Liu C. Y et al. (2014) | |
| Esophageal squamous cell cancer | 90% (36/40) | - | ×c | Qu et al. (2012) |
| Esophageal adenocarcinoma | 97.3% (110/113) | × | + | Rantanen et al. (2013) |
| Gastric cancer | 65% (145/223) | + | + | Khanna et al. (2009) |
| 67.6% (25/37) | + | + | Chen F. F et al. (2015) | |
| Esophagogastric junction adenocarcinoma | 64.6% (42/65) | + | - | Li et al. (2019) |
| Colorectal cancer | 87.9% (661/752) | × | × | Böckelman et al. (2012) |
| 100% (167/167) | + | + | Teng et al. (2012) | |
| 89.4% (93/104) | + | + | Wiegering et al. (2013) | |
| 80.7% (21/26) | + | + | Chen et al. (2020) | |
| HCC | 100% (136/136) | + | + | He et al. (2012) |
| 77.9% d (106/136) | + | + | Huang C. Y et al. (2012) | |
| Pancreatic cancer | 56.3% (54/96) | + | + | Wang et al. (2013) |
| 70.8% (51/72) | + | + | Xu et al. (2016) | |
| Cholangiocarcinoma | 78.9% (45/57) | + | + | Xu et al. (2013) |
| Renal cancer | 70.1% (75/107) | + | + | Ren et al. (2011) |
| 50.0% (55/110) | + | + | Wang P et al. (2019) | |
| 73.7% d (59/80) | - | + | Gao et al. (2020) | |
| Bladder cancer | 72.6% (85/117) | + | + | Xue et al. (2013) |
| 78.8% (63/80) | - | - | Pang et al. (2016) | |
| 41.9% (18/43) | - | - | Huang P et al. (2012) | |
| Prostate cancer | 72.9% (43/59) | × | × | Vaarala et al. (2010) |
| 96.2% (101/105) | - | × | Celikden et al. (2020) | |
| Cervical cancer | 52.8% (38/72) | - | - | Liu X et al. (2014) |
| 60.8% (31/51) | - | - | Wu et al. (2015) | |
| Ovarian cancer | 82.8% (434/524) | + | + | Böckelman et al. (2011a) |
| 65.8% (100/152) | - | - | Fang et al. (2012) | |
| Melanoma | 100.0% (65/65) | + | + | Shi et al. (2014) |
| Multiple myeloma | 46.3% (19/41) | - | + | Liu et al. (2017c) |
| Osteosarcoma | 76.5% (39/51) | - | - | Zhai et al. (2014) |
| AML | 57.8% d (67/116) | - | - | Wang et al. (2011) |
| 100% d (203/203) | + | + | Barragán et al. (2015) | |
| CML | 75.7% d (56/74) | - | - | Wang J et al. (2014) |
a
Related.
b
Unknown.
c
Unrelated.
d
CIP2A mRNA, positive rate (the rest was CIP2A protein positive rate).